340 related articles for article (PubMed ID: 30239528)
1. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
Sugay J
Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
[TBL] [Abstract][Full Text] [Related]
2. Approval Process: An Overview of Biosimilars in the Oncology Setting.
Sowinski-Raff L
Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
[TBL] [Abstract][Full Text] [Related]
3. Nursing Roles: Clinical Implications Regarding Trends, Administration, and Education for Biosimilars in Oncology Practice.
Zack E
Clin J Oncol Nurs; 2018 Oct; 22(5):21-26. PubMed ID: 30239530
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
7. Big Data and Pharmacovigilance: The Role of Oncology Nurses.
Glenn DG
Clin J Oncol Nurs; 2016 Oct; 20(5):478-80. PubMed ID: 27668367
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars: Exploring the History, Science, and Progress.
Tariman JD
Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
[TBL] [Abstract][Full Text] [Related]
10. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
[TBL] [Abstract][Full Text] [Related]
13. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
16. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
17. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in oncology: key role of nurses in patient education.
Waller CF; Friganović A
Future Oncol; 2020 Sep; 16(25):1931-1939. PubMed ID: 32618476
[TBL] [Abstract][Full Text] [Related]
20. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
